Challenging the Standard Immunogenicity Assessment Approach: 1-Tiered ADA Testing Strategy in Clinical Trials
Authors:
- 12 December 2024
- journal article
- research article
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (1) , 1-11
Abstract
The ADA testing strategy for protein therapeutics was established almost two decades ago when assay methodologies were rudimentary, and serious immunogenicKeywords
This publication has 19 references indexed in Scilit:
- Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2023
- User's guide to correlation coefficientsTurkish Journal of Emergency Medicine, 2018
- Lipid-Reduction Variability and Antidrug-Antibody Formation with BococizumabNew England Journal of Medicine, 2017
- Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid TumorsThe Journal of Clinical Pharmacology, 2016
- Correlation of screening and confirmatory results in tiered immunogenicity testing by solution-phase bridging assaysJournal of Pharmaceutical and Biomedical Analysis, 2013
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-upJAMA, 2011
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseNew England Journal of Medicine, 2008
- Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsJournal of Immunological Methods, 2004
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002